all report title image
  • Published On : Dec 2019
  • Code : CMI2643
  • Industry : Pharmaceutical
  • Pages : 308
  • Formats :

Autism Spectrum Disorder (ASD) is a neurodegenerative disorder, which is associated and often overlaps with other conditions such as epilepsy, frequent infections, sleep disorders, anxiety, depression, and gastrointestinal problems. ASD is only diagnosed by developmental and comprehensive tests. It can be detected at eighteen months to two years of age. Drugs such as Aripiprazole, Risperidone, and Melatonin are U.S. Food and Drug Administration (FDA) approved drugs that aid in the treatment of ASD. Bumetanide and Balovaptan are the drugs that are under clinical trial and investigation to evaluate their safety and efficacy for the treatment of ASD. 

The global autism spectrum disorder therapeutics (ASD) therapeutics market size was valued at US$ 2,285.5 million in 2019, and is expected to witness a CAGR of 10.9% over the forecast period (2019 – 2027).

Global Autism Spectrum Disorder Therapeutics Market Share (%) Analysis, By Drug Type, 2019

Autism Spectrum Disorder Therapeutics  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2019)

Increasing Number of Pipeline Drugs and Early Diagnosis of ASD is expected to Drive Growth of the Autism Spectrum Disorder Therapeutics Market

Increasing number of pipeline drugs and launches of novel products by key players are expected to be the major driving factors for the global autism spectrum disorder therapeutics market growth during the forecast period. For instance, in February 2014, the company was awarded six new patents for its enzyme delivery system in Europe, Australia, and Central America, which can be utilized for multiple enzyme products including CM-AT— Curemark’s proprietary ASD drug.

Furthermore, in September 2017, Curemark conducted second Phase III clinical trial: Blüm Study— to evaluate the safety and efficacy of CM-AT in children aged 3-8 with ASD.

Moreover, earlier diagnosis of ASD can aid in the development of children. For instance, according to the research published in the JAMA Pediatrics journal in April 2019, accurate diagnosis of ASD at earlier than 18 months is feasible and there may be opportunities to test the usefulness of ASD treatment at an early age. Therefore, increasing research on ASD is expected to create a favorable environment for autism spectrum disorder therapeutics market growth over the forecast period.

Autism Spectrum Disorder Therapeutics Market - Restraints

Shortage of specialist doctors to diagnose ASD accurately is one of the major factors, which is expected to hamper the ASD therapeutics market. For instance, according to Simons Foundation Autism Research Initiative’s (SFARI) research, in 2018, there are only 8,300 child psychiatrists, 1,500 child neurologists, and 1,000 developmental-behavioral pediatricians for over 1 million autistic children in the U.S. The shortage of specialist doctors to diagnose ASD hampers growth of the ASD therapeutic market.

Autism Spectrum Disorder Therapeutics Market - Regional Insights

On the basis of region, the global autism spectrum disorder therapeutics market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global autism spectrum disorder therapeutics market during the forecast period, owing to increasing prevalence of ASD in the pediatric population of the U.S. For instance, according to the Centers for Disease Control and Prevention’s (CDC) report released in April 2018, 1 in every 59 children was identified with ASD in the age range of 3 to 17 years in 2014.

Asia Pacific is expected to foresee a rapid growth in the autism spectrum disorder therapeutics market revenue. This is owing to increase in sales of Aripiprazole for the treatment of ASD. For instance, in 2017, Otsuka Pharmaceutical’s ABILIFY MAINTENA (Aripiprazole) generated US$ 62.9 million in revenue with a growth of 24.1% compared to the revenue in 2016. Moreover, ABILIFY accounted for a revenue of US$ 59.7 million in 2017.

Global Autism Spectrum Disorder Therapeutics Market Value (US$ Mn) & Y-o-Y Growth (%) 2016-2027

Autism Spectrum Disorder Therapeutics  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2019)

Autism Spectrum Disorder Therapeutics Market - Competitive Landscape

Key players operating in the global autism spectrum disorder therapeutics market include, F. Hoffmann-La Roche AG, Neurim Pharmaceuticals, Inc., Yamo Pharmaceuticals LLC, Servier Laboratories Ltd., Otsuka Holdings Co. Ltd., Curemark LLC, Oryzon Genomics S.A., GW Pharmaceuticals Plc., Teva Pharmaceutical Industries Ltd., Zynerba Pharmaceuticals Inc., Stalicla SA., Novartis AG, Pfizer, Inc., and Bristol Myers Squibb.

Autism, scientifically referred as Autism Spectrum Disorder Therapeutics (ASD) is a complex neurological disorder that is characterized by symptoms including challenges with social skills, repetitive behaviours, as well as issues with speech and non-verbal communication. Major companies operating in the ASD therapeutics market are focusing on extensive research & development and clinical trials to introduce new drugs. For instance, in February 2019, Servier Laboratories Ltd. and Neurochlore announced the launch of phase 3 studies to evaluate the use of Bumetanide in children with ASD. Bumetanide is typically used to treat fluid retention (edema) and high blood pressure.

Market Dynamics

Increasing prevalence of ASD worldwide is expected to boost the Autism Spectrum Disorder Therapeutics (ASD) therapeutics market growth. For instance, according to the data published in Our World in Data in 2017, around 62 million people worldwide were estimated to have ASD in 2016. Moreover, under 50 million of these cases were found in males. Of this 62 million with ASD, around 18 million had only Autism and 44 million had Asperger syndrome and other spectrum disorders.

However, stringent regulations and continuous watch employed by governing authorities for product approval and marketing of medicines can act as a potential hindrance for growth of the autism spectrum disorder therapeutics market. For instance, in May 2017, the U.S. Food and Drug Administration (FDA) shut down operations of Louisiana-based Pick and Pay Inc. Cili Minerals, a manufacturer of drug and dietary supplements, after finding that the company was falsely marketing products as being able to treat autism.

Key features of the study:

  • This report provides in-depth analysis of the autism spectrum disorder therapeutics market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2019 – 2027, considering 2018 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global autism spectrum disorder therapeutics market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include, F. Hoffmann-La Roche AG, Neurim Pharmaceuticals, Inc., Yamo Pharmaceuticals LLC, Servier Laboratories Ltd., Otsuka Holdings Co. Ltd., Curemark LLC, Oryzon Genomics S.A., GW Pharmaceuticals Plc., Teva Pharmaceutical Industries Ltd., Zynerba Pharmaceuticals Inc., Stalicla SA., Novartis AG, Pfizer, Inc., and Bristol Myers Squibb
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global autism spectrum disorder therapeutics market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for Autism Spectrum Disorder Therapeutics market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Autism Spectrum Disorder Therapeutics Market, By Drug Type:
    • Aripiprazole
    • Risperidone
    • Melatonin
    • CM-AT
    • Bumetanide
    • Balovaptan
  • Global Autism Spectrum Disorder Therapeutics Market, By Age Group:
    • Child
    • Adult
  • Global Autism Spectrum Disorder Therapeutics Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Autism Spectrum Disorder Therapeutics Market, By Region:
    • North America
      • By Country:
        • U.S.
          • By Drug Type:
            • Aripiprazole
            • Risperidone
            • Melatonin
            • CM-AT
            • Bumetanide
            • Balovaptan
          • By Age Group:
            • Child
            • Adult
          • By Distribution Channel:
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Canada
          • By Drug Type:
            • Aripiprazole
            • Risperidone
            • Melatonin
            • CM-AT
            • Bumetanide
            • Balovaptan
          • By Age Group:
            • Child
            • Adult
          • By Distribution Channel:
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
    • Europe
      • By Country:
        • U.K.
          • By Drug Type:
            • Aripiprazole
            • Risperidone
            • Melatonin
            • CM-AT
            • Bumetanide
            • Balovaptan
          • By Age Group:
            • Child
            • Adult
          • By Distribution Channel:
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Germany
          • By Drug Type:
            • Aripiprazole
            • Risperidone
            • Melatonin
            • CM-AT
            • Bumetanide
            • Balovaptan
          • By Age Group:
            • Child
            • Adult
          • By Distribution Channel:
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Italy
          • By Drug Type:
            • Aripiprazole
            • Risperidone
            • Melatonin
            • CM-AT
            • Bumetanide
            • Balovaptan
          • By Age Group:
            • Child
            • Adult
          • By Distribution Channel:
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Spain
          • By Drug Type:
            • Aripiprazole
            • Risperidone
            • Melatonin
            • CM-AT
            • Bumetanide
            • Balovaptan
          • By Age Group:
            • Child
            • Adult
          • By Distribution Channel:
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • France
          • By Drug Type:
            • Aripiprazole
            • Risperidone
            • Melatonin
            • CM-AT
            • Bumetanide
            • Balovaptan
          • By Age Group:
            • Child
            • Adult
          • By Distribution Channel:
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Russia
          • By Drug Type:
            • Aripiprazole
            • Risperidone
            • Melatonin
            • CM-AT
            • Bumetanide
            • Balovaptan
          • By Age Group:
            • Child
            • Adult
          • By Distribution Channel:
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Rest of Europe
          • By Drug Type:
            • Aripiprazole
            • Risperidone
            • Melatonin
            • CM-AT
            • Bumetanide
            • Balovaptan
          • By Age Group:
            • Child
            • Adult
          • By Distribution Channel:
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
    • Asia Pacific
      • By Country:
        • China
          • By Drug Type:
            • Aripiprazole
            • Risperidone
            • Melatonin
            • CM-AT
            • Bumetanide
            • Balovaptan
          • By Age Group:
            • Child
            • Adult
          • By Distribution Channel:
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Japan
          • By Drug Type:
            • Aripiprazole
            • Risperidone
            • Melatonin
            • CM-AT
            • Bumetanide
            • Balovaptan
          • By Age Group:
            • Child
            • Adult
          • By Distribution Channel:
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • India
          • By Drug Type:
            • Aripiprazole
            • Risperidone
            • Melatonin
            • CM-AT
            • Bumetanide
            • Balovaptan
          • By Age Group:
            • Child
            • Adult
          • By Distribution Channel:
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • ASEAN
          • By Drug Type:
            • Aripiprazole
            • Risperidone
            • Melatonin
            • CM-AT
            • Bumetanide
            • Balovaptan
          • By Age Group:
            • Child
            • Adult
          • By Distribution Channel:
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Australia
          • By Drug Type:
            • Aripiprazole
            • Risperidone
            • Melatonin
            • CM-AT
            • Bumetanide
            • Balovaptan
          • By Age Group:
            • Child
            • Adult
          • By Distribution Channel:
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • South Korea
          • By Drug Type:
            • Aripiprazole
            • Risperidone
            • Melatonin
            • CM-AT
            • Bumetanide
            • Balovaptan
          • By Age Group:
            • Child
            • Adult
          • By Distribution Channel:
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Rest of Asia Pacific
          • By Drug Type:
            • Aripiprazole
            • Risperidone
            • Melatonin
            • CM-AT
            • Bumetanide
            • Balovaptan
          • By Age Group:
            • Child
            • Adult
          • By Distribution Channel:
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
    • Latin America
      • By Country:
        • Brazil
          • By Drug Type:
            • Aripiprazole
            • Risperidone
            • Melatonin
            • CM-AT
            • Bumetanide
            • Balovaptan
          • By Age Group:
            • Child
            • Adult
          • By Distribution Channel:
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Mexico
          • By Drug Type:
            • Aripiprazole
            • Risperidone
            • Melatonin
            • CM-AT
            • Bumetanide
            • Balovaptan
          • By Age Group:
            • Child
            • Adult
          • By Distribution Channel:
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Argentina
          • By Drug Type:
            • Aripiprazole
            • Risperidone
            • Melatonin
            • CM-AT
            • Bumetanide
            • Balovaptan
          • By Age Group:
            • Child
            • Adult
          • By Distribution Channel:
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Rest of Latin America
          • By Drug Type:
            • Aripiprazole
            • Risperidone
            • Melatonin
            • CM-AT
            • Bumetanide
            • Balovaptan
          • By Age Group:
            • Child
            • Adult
          • By Distribution Channel:
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
    • Middle East
      • By Country:
        • GCC
          • By Drug Type:
            • Aripiprazole
            • Risperidone
            • Melatonin
            • CM-AT
            • Bumetanide
            • Balovaptan
          • By Age Group:
            • Child
            • Adult
          • By Distribution Channel:
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Israel
          • By Drug Type:
            • Aripiprazole
            • Risperidone
            • Melatonin
            • CM-AT
            • Bumetanide
            • Balovaptan
          • By Age Group:
            • Child
            • Adult
          • By Distribution Channel:
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Rest of Middle East
          • By Drug Type:
            • Aripiprazole
            • Risperidone
            • Melatonin
            • CM-AT
            • Bumetanide
            • Balovaptan
          • By Age Group:
            • Child
            • Adult
          • By Distribution Channel:
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
    • Africa
      • By Country/Region:
        • South Africa
          • By Drug Type:
            • Aripiprazole
            • Risperidone
            • Melatonin
            • CM-AT
            • Bumetanide
            • Balovaptan
          • By Age Group:
            • Child
            • Adult
          • By Distribution Channel:
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Central Africa
          • By Drug Type:
            • Aripiprazole
            • Risperidone
            • Melatonin
            • CM-AT
            • Bumetanide
            • Balovaptan
          • By Age Group:
            • Child
            • Adult
          • By Distribution Channel:
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • North Africa
          • By Drug Type:
            • Aripiprazole
            • Risperidone
            • Melatonin
            • CM-AT
            • Bumetanide
            • Balovaptan
          • By Age Group:
            • Child
            • Adult
          • By Distribution Channel:
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
  • Company Profiles
    • F. Hoffmann-La Roche AG.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Neurim Pharmaceuticals, Inc.
    • Yamo Pharmaceuticals LLC
    • Servier Laboratories Ltd.
    • Otsuka Holdings Co. Ltd.
    • Curemark LLC
    • Oryzon Genomics S.A.
    • GW Pharmaceuticals Plc.
    • Teva Pharmaceutical Industries Ltd.
    • Zynerba Pharmaceuticals Inc.
    • Stalicla SA.
    • Novartis AG
    • Pfizer, Inc.
    • Bristol Myers Squibb.

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The global autism spectrum disorder therapeutics market is estimated to surpass US$ 5,225.5 Million by 2027.
Major players operating in the global autism spectrum disorder therapeutics market include F. Hoffmann-La Roche AG, Neurim Pharmaceuticals, Inc., Yamo Pharmaceuticals LLC, Servier Laboratories Ltd., Otsuka Holdings Co. Ltd., Curemark LLC, Oryzon Genomics S.A., GW Pharmaceuticals Plc., Teva Pharmaceutical Industries Ltd., Zynerba Pharmaceuticals Inc., Stalicla SA., Novartis AG, Pfizer, Inc., and Bristol Myers Squibb.
Lack of specialist doctors to diagnose autism spectrum disorder accurately is one of the major factors is one of the major factors that is expected to hamper growth of the market over the forecast period.
Increasing number of pipeline drugs and launches of novel products by key players are some of the major factors that are expected to propel growth of the market over the forecast period.
The global autism spectrum disorder therapeutics market is estimated to exhibit a CAGR of 10.9% over the forecast period.
Among regions, North America is expected to hold dominant position in the global autism spectrum disorder therapeutics market over the forecast period.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo